Business
Novo Nordisk CEO Maziar Mike Doustdar acknowledged the market pressure facing the company’s GLP-1 products but sought to assure investors that Novo has the situation under control.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Approximately 100 cases of COVID-19 have been linked to a Biogen corporate meeting, as reported by a local media station in the Boston area.
‘Flatten the Curve’ is sure to become a phrase forever linked with COVID-19. It refers to doing all we can as individuals to slow the spread of COVID-19 so that all available resources can be used for those who need them most urgently.
Work in the age of COVID-19 is in flux. Restrictions change daily, and life sciences researchers are finding their work lives considerably different than they were a few short weeks ago.
There has been something of a furor over reports in the German newspaper Welt am Sonntag that claimed the Trump administration offered a “billion dollars” for exclusive rights to a coronavirus vaccine in development by German company CureVac, “but only for the USA.”
The two companies will focus on BioNTech’s BNT162, an mRNA-based vaccine candidate.
Restricting face-to-face interactions with people will go a long way in limiting the spread of the virus.
Inside the U.S., the first clinical trial for a vaccine to the novel coronavirus that causes COVID-19 began today.
The companies intend to push the vaccine candidate into human trials by April of this year, subject to regulatory approval.
Consumer healthcare company HRA Pharma grew their total group revenues by 20.8% in 2019 with EBITDA growing by 30%
Arie Belldegrun, the co-founder and executive chairman of the board of Allogene, disclosed this weekend that he has been diagnosed with COVID-19. The pharma entrepreneur is in self-quarantine and is doing well.